A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.

@article{Colombo2012API,
  title={A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.},
  author={Nicoletta Colombo and Giorgia Mangili and Serafina Mammoliti and M{\aa}rten Kalling and Bengt Tholander and Lars Axel Sternas and Giliane Buzenet and Donald H Chamberlain},
  journal={Gynecologic oncology},
  year={2012},
  volume={125 1},
  pages={42-7}
}
OBJECTIVE The recombinant fusion protein, aflibercept binds and neutralizes vascular endothelial growth factor (VEGF) A, B and placental growth factor (PlGF). Aflibercept inhibits ascites formation and reduces tumor burden in an ovarian cancer model. This open-label, single-arm, multicenter phase II study assessed the efficacy and safety of aflibercept in patients with advanced chemo-resistant epithelial ovarian cancer and symptomatic malignant ascites. METHODS Patients who required ≥3… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
35 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…